Latest news for Delegat Group (OTC:DGLLF) Stock

Delegat Group Ltd is a wine production and distribution company. It markets its products under the Oyster Bay and Barossa Valley Estate brands. The group's primary source of revenue is derived by providing wine to third-party retailers and distributors. Its segments are Delegat Limited, Delegat Australia Pty Ltd, Delegat Europe Limited, Delegat USA, Inc, and Others. The group generates the majority of the revenue from Delegat Limited. It sells and markets its product through a combination of subsidiary companies based overseas or to customers and distributors directly in the New Zealand, Canadian, Asian and Pacific Island markets. Rest of the segments act as distributors and supports in the marketing of the products in their respective geographic regions.

DELEGATS GROUP LTD by DELEGATS GROUP LTD.

Delegat Group Ltd

News

Contracts

TechnipFMC Awarded iEPCI Contract For Energean's Katlan Development; Contract Between $500M-$1B

Dover Acquires Demaco Holland; Financial Terms Not Disclosed

Guidance

Abacus Life Reports Preliminary Q2 Total Revenue Of $28M - $30M, Up 146-163% Y/Y (Est $21.893M)

<p>Alpine Income Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.39 by 10.26 percent. This is a 16.22 percent increase over earnings of $0.37 per share from the same period last year.  The company reported quarterly sales of $12.49 million which beat the analyst consensus estimate of $11.96 million by 4.43 percent.  This is a 9.19 percent increase over sales of $11.44 million the same period last year.</p>


Earnings

Earnings Beats

PINE

Alpine Income Prop Trust Q2 FFO $0.43 Beats $0.39 Estimate, Sales $12.49M Beat $11.96M Estimate

<p>Scholastic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) reported quarterly earnings of $1.73 per share which missed the analyst consensus estimate of $2.66 by 34.96 percent. This is a 23.45 percent decrease over earnings of $2.26 per share from the same period last year.  The company reported quarterly sales of $474.900 million which missed the analyst consensus estimate of $552.496 million by 14.04 percent.  This is a 10.11 percent decrease over sales of $528.300 million the same period last year.</p>


Earnings Misses

SCHL

Scholastic Q4 2024 Adj EPS $1.73 Misses $2.66 Estimate, Sales $474.900M Miss $552.496M Estimate

<p>Amcon Distributing (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DIT#AMEX">DIT</a>) reported quarterly earnings of $2.46 per share. This is a 62.67 percent decrease over earnings of $6.59 per share from the same period last year.  The company reported $717.85 million in sales this quarter. This is a 3.07 percent increase over sales of $696.49 million the same period last year.</p>


Amcon Distributing Q3 EPS $2.46 Down From $6.59 YoY, Sales $717.85M Up From $696.49M YoY

<p>Event To Air At 7pm ET On Gray-Owned Local TV Stations Including Peachtree TV In Atlanta And Over Ninety Other Markets</p>


Harlem Globetrotters And Gray Media Announce Live Broadcast Of Game From American Dream In New Jersey On August 18, 2024

<p>OceanFirst Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCFC#NASDAQ">OCFC</a>) reported quarterly earnings of $0.40 per share which missed the analyst consensus estimate of $0.43 by 6.98 percent.  The company reported quarterly sales of $82.300 million which missed the analyst consensus estimate of $85.459 million by 3.70 percent.  This is a 10.65 percent decrease over sales of $92.109 million the same period last year.</p>


OCFC

OceanFirst Financial Q2 2024 GAAP EPS $0.40 Misses $0.43 Estimate, Sales $82.300M Miss $85.459M Estimate

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Boston Scientific</strong>.</p>
<p>Looking at options history for Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) we detected 16 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 50% with bearish.</p>
<p>From the overall spotted trades, 9 are puts, for a total amount of $581,474 and 7, calls, for a total amount of $816,242.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $72.5 and $80.0 for Boston Scientific, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Boston Scientific's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Boston Scientific's significant trades, within a strike price range of $72.5 to $80.0, over the past month.</p>
<h3>Boston Scientific Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721333775_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$75.00</td>
<td>$300.0K</td>
<td>2.5K</td>
<td>307</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$3.1</td>
<td>$2.95</td>
<td>$3.1</td>
<td>$75.00</td>
<td>$289.2K</td>
<td>2.5K</td>
<td>1.3K</td>
</tr>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$75.00</td>
<td>$237.5K</td>
<td>18.9K</td>
<td>139</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$1.6</td>
<td>$1.45</td>
<td>$1.6</td>
<td>$80.00</td>
<td>$97.3K</td>
<td>18.0K</td>
<td>94</td>
</tr>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.2</td>
<td>$75.00</td>
<td>$79.7K</td>
<td>4.6K</td>
<td>693</td>
</tr>
</tbody>
</table>
</p>
<h3>About Boston Scientific</h3>
<p>Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.</p>
<p>Following our analysis of the options activities associated with Boston Scientific, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Boston Scientific Standing Right Now?</h3>
<ul>
<li>With a trading volume of 9,408,216, the price of BSX is down by -2.4%, reaching $75.55.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
<h3>What The Experts Say On Boston Scientific</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $86.2.</p>
<ul>
<li>An analyst from Citigroup has decided to maintain their Buy rating on Boston Scientific, which currently sits at a price target of $90. </li>
<li>An analyst from TD Cowen persists with their Buy rating on Boston Scientific, maintaining a target price of $86. </li>
<li>Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Boston Scientific with a target price of $81. </li>
<li>Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Boston Scientific with a target price of $84. </li>
<li>An analyst from Truist Securities has decided to maintain their Buy rating on Boston Scientific, which currently sits at a price target of $90. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Boston Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Behind the Scenes of Boston Scientific's Latest Options Trends

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Altria Group</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MO, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Altria Group.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 57% bullish and 28%, bearish.</p>
<p>Out of all of the special options we uncovered, 8 are puts, for a total amount of $576,352, and 6 are calls, for a total amount of $356,008.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $35.0 to $60.0 for Altria Group over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Altria Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Altria Group's significant trades, within a strike price range of $35.0 to $60.0, over the past month.</p>
<h3>Altria Group Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721333770_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.45</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$47.50</td>
<td>$198.4K</td>
<td>604</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>MO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$4.8</td>
<td>$4.7</td>
<td>$4.73</td>
<td>$45.00</td>
<td>$151.5K</td>
<td>4.6K</td>
<td style="text-align: right;">105</td>
</tr>
<tr>
<td>MO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.7</td>
<td>$5.55</td>
<td>$5.7</td>
<td>$50.00</td>
<td>$71.2K</td>
<td>349</td>
<td style="text-align: right;">452</td>
</tr>
<tr>
<td>MO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.35</td>
<td>$11.6</td>
<td>$11.6</td>
<td>$60.00</td>
<td>$58.0K</td>
<td>9</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>MO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.76</td>
<td>$2.7</td>
<td>$2.7</td>
<td>$50.00</td>
<td>$56.9K</td>
<td>296</td>
<td style="text-align: right;">647</td>
</tr>
</tbody>
</table>
</p>
<h3>About Altria Group</h3>
<p>Altria comprises Philip Morris USA, us Smokeless Tobacco, John Middleton, Horizon Innovations, and Helix Innovations. Through its tobacco subsidiaries, Altria maintains the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the us with 42% annual share in 2023. Beyond its core business, it holds an 8% interest in the world's largest brewer, Anheuser-Busch InBev, a 42% stake in cannabis manufacturer Cronos, acquired Njoy Holdings in 2023, and operates a joint venture with Japan Tobacco in the heated tobacco category. It also recently disposed of its investment in Juul Labs.</p>
<h3>Present Market Standing of Altria Group</h3>
<ul>
<li>With a trading volume of 6,740,395, the price of MO is down by -0.12%, reaching $49.33.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 13 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Altria Group</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $48.0.</p>
<ul>
<li>An analyst from B of A Securities has decided to maintain their Neutral rating on Altria Group, which currently sits at a price target of $48. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Altria Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Market Whales and Their Recent Bets on Altria Group Options

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Celestica</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CLS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Celestica.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 12% bullish and 62%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $206,614, and 3 are calls, for a total amount of $110,431.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $47.5 to $70.0 for Celestica during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Celestica's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Celestica's substantial trades, within a strike price spectrum from $47.5 to $70.0 over the preceding 30 days.</p>
<h3>Celestica Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721333765_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CLS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$2.15</td>
<td>$2.1</td>
<td>$2.15</td>
<td>$47.50</td>
<td>$84.0K</td>
<td style="text-align: right;">370</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$7.9</td>
<td>$5.4</td>
<td>$6.05</td>
<td>$65.00</td>
<td>$60.0K</td>
<td style="text-align: right;">319</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>CLS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$4.4</td>
<td>$4.3</td>
<td>$4.4</td>
<td>$52.50</td>
<td>$36.9K</td>
<td style="text-align: right;">62</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CLS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$10.7</td>
<td>$10.6</td>
<td>$10.7</td>
<td>$65.00</td>
<td>$31.0K</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CLS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.1</td>
<td>$11.6</td>
<td>$12.7</td>
<td>$60.00</td>
<td>$27.9K</td>
<td style="text-align: right;">106</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Celestica</h3>
<p>Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.</p>
<p>In light of the recent options history for Celestica, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Celestica</h3>
<ul>
<li>Currently trading with a volume of 2,868,164, the CLS's price is down by -0.91%, now at $56.32. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Celestica options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Celestica Options Trading: A Deep Dive into Market Sentiment

<p>Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDB#NASDAQ">INDB</a>) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.11 by 9.01 percent. This is a 14.79 percent decrease over earnings of $1.42 per share from the same period last year.</p>


INDB

Independent Bank Q2 EPS $1.21 Beats $1.11 Estimate

WIIM

PPG shares are trading lower after the company cut its FY24 outlook.

<p>CNB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCNE#NASDAQ">CCNE</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.51 by 9.8 percent. This is a 8.2 percent decrease over earnings of $0.61 per share from the same period last year.  The company reported quarterly sales of $45.72 million which beat the analyst consensus estimate of $45.70 million by 0.04 percent.  This is a 3.26 percent decrease over sales of $47.26 million the same period last year.</p>


CCNE

CNB Financial Q2 EPS $0.56 Beats $0.51 Estimate, Sales $45.72M Beat $45.70M Estimate

<p><a href="https://www.globenewswire.com/Tracker?data=_-tupevdZyNLPOnQuWoJlepbaAjvZk4pAsOkfteCCkOhiR3KL0nk4fqrk7O3CCoZkcUViXpBOLiej-a3Uu7oXN8IKLN0cQe_bUBLdq_yI_o=">Vigil Neuroscience, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations highlighting its oral small molecule VG-3927 at the 2024 Alzheimer's Association International Conference (AAIC)taking place on July 28-August 1, 2024 in Philadelphia, Pennsylvania and virtually.</p>


Biotech

General

VIGL

Vigil To Present Its Small Molecule TREM2 Agonist VG-3927 At The 2024 Alzheimer's Association International Conference On July 28-August 1, 2024

Scholastic shares are trading lower after the company reported Q4 financial results.

<p>First Finl Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIN#NASDAQ">FFIN</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.36 by 2.78 percent. This is a 2.78 percent increase over earnings of $0.36 per share from the same period last year.</p>


FFIN

First Finl Bankshares Q2 EPS $0.37 Beats $0.36 Estimate

NVOS

Novo Integrated Sciences shares are trading higher after the company announced that it received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit and monetization program.

PPG Revises FY24 Organic Sales Growth Outlook To Flat To Up Low Single Digits (Prior View Up Low Single Digits); Cuts Adj EPS Outlook From $8.34 - $8.59 To $8.15 - $8.30 (Est $8.41)

<p>AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.85 by 3.53 percent.  The company reported quarterly sales of $657.00 million which missed the analyst consensus estimate of $658.93 million by 0.29 percent.  This is a 18.74 percent increase over sales of $553.30 million the same period last year.</p>


-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Delegat Group

News

Latest news for Delegat Group (OTC:DGLLF) Stock